Cross-Cultural Adaptation, Validity and Reliability of the Turkish Version of the Adolfsson-Björnsson Upper Extremity Activity Scale (ABAS)

December 29, 2025 updated by: Dilek Hande Esen, Mustafa Kemal University

Cross-Cultural Adaptation, Validity and Reliability of the Turkish Version of the Adolfsson-Björnsson Upper Extremity Activity Scale (ABAS) in Individuals With Upper Extremity Injuries

Activity limitation is a common problem in individuals with upper extremity disorders. Many conditions involving the shoulder complex such as traumatic and non-traumatic upper extremity pain, subacromial impingement, postoperative pain, rotator sheath tears, rotator sheath tendinopathy, shoulder arthritis, adhesive capsulitis, shoulder instabilities may lead to limitations in activities of daily living due to pain and/or symptoms. Therefore, evaluation of upper extremity activities and determination of possible limitations have an important place in the management of the disease process.

Until now, symptom-related activities of daily living in patients with upper limb disorders have often been assessed with the Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH) and the Shoulder Pain and Disability Index (SPADI). However, in the development of these scales, only statements describing specific activities were used and items were not scored from easy to difficult according to activity level. There is no scale specifically developed for upper extremity pathologies that grades upper extremity activity level according to a certain level of difficulty. In order to fill this gap in the literature, Adolfsson et al. developed 'The Adolfsson-Björnsson Upper Extremity Activity Scale (ABAS)' to evaluate activities of daily living according to the perceived difficulty level in individuals with upper extremity injuries. Cross-cultural adaptation, validity and reliability of the Turkish version of the ABAS have not been studied.

The aim of this study was to make a cross-cultural Turkish adaptation of the 'The Adolfsson-Björnsson Upper Extremity Activity Scale (ABAS)' and to investigate the validity, reliability and psychometric properties of the Turkish version on individuals with upper extremity disorders.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The research will be conducted at Gazi University Department of Physical Therapy and Rehabilitation, Athlete Health Unit. The research will be conducted according to the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) guidelines.

Translation and cross-cultural adaptation of the ABAS will be carried out in five stages according to standard guidelines for scale translation and cross-cultural adaptation. It was planned to include 150 individuals with upper extremity disorders between the ages of 18 to 64 in the study.

The data collection for this planned study will be solely through surveys. The design of the study is a cross-sectional study aimed at developing and assessing the validity and reliability." Surveys specific to the research will be implemented in the study.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Turkey (Türkiye)
    • Mersi̇n
      • Yenişehir, Mersi̇n, Turkey (Türkiye), 33140
        • Toros Üniversitesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Patients with upper extremity injury, who can read and write Turkish and are between the ages of 18-64, and only participants with unchanged health status for retesting will be included in the study. Patients with mental and neurological disorders (major depression, schizophrenia, psychosis, stroke, cerebral palsy, etc.) and/or rheumatological disease, active local or systemic infection, cancer history, severe visual impairment, need for emergency surgery, injection in the last 3 years, sensory problems that may affect the application of scales and cognitive impairment will be excluded from the study.

Description

Inclusion Criteria:

  • Patients with upper extremity injury, who can read and write Turkish and are between the ages of 18-64

Exclusion Criteria:

  • Mental and neurological disorders (major depression, schizophrenia, psychosis, stroke, cerebral palsy, etc.) and/or rheumatological disease, active local or systemic infection, cancer history, severe visual impairment, need for emergency surgery, injection in the last 3 years, sensory problems that may affect the application of scales and cognitive impairment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Patients with upper limb injuries

Patients with upper extremity injury, who can read and write Turkish and are between the ages of 18-64, and only participants with unchanged health status for retesting will be included in the study.

Patients with mental and neurological disorders (major depression, schizophrenia, psychosis, stroke, cerebral palsy, etc.) and/or rheumatological disease, active local or systemic infection, cancer history, severe visual impairment, need for emergency surgery, injection in the last 3 years, sensory problems that may affect the application of scales and cognitive impairment will be excluded from the study.
Other: No intervention
No intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Investigating Cross-Cultural Adaptation, Validity and Reliability of the Turkish Version of The Adolfsson-Björnsson Activity Scale (ABAS) with upper ekstremity injuries
Time Frame: 1 weeks
The scale items consist of 8 different categories. The increase in the mean of the questionnaire from category 1 to 8 indicates that the upper extremity is used in higher level activities.
1 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Mustafa Kemal University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Dilek Hande Esen, PhD, Toros University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 29, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 28, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 28, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 4, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 31, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 29, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E-77082166-604.01.02-809466

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Reliability and Validity

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings